FUTURE OF MEDICINE
Largest licensed manufacturer of medical grade cell products in South East Asia.
World’s first published paper studying stem cell to treat genetic blindness through subtenon injection.
More than 20,000 clinical study subjects, includes but not limited to acute myocardial infarction, stroke, autism, diabetes and etc.
Incorporated in 2018, 23 Century International Life Science Centre is a clinical-stage biopharmaceutical company engaged in the discovery, research, development and commercialisation of regenerative medicine in stem cell therapy. Part of what we do involves developing approaches in regenerative medicine that allows us to develop treatments which target diseases and help the human body heal, recover and repair itself from disease and injury within its natural capacity.
Founded in 2017, Shenzhen 23 Century represents a group of investors collectively invested more than 40 million to set up largest stem cell laboratory in South East Asia, namely, 23 Century International Life Science Centre, located in Seri Kembangan, Malaysia.
Beike is the leading global provider of stem cell treatments, specializing in the research, development, and clinical application of adult stem cells. Today, Beike remains at the forefront of adult stem cell research and development globally, offering innovative treatment options for currently incurable diseases and chronic illnesses that are still difficult for clinicians to treat.
